Veristat Congratulates George Medicines on FDA Approval of WIDAPLIK™
Proud to Collaborate in Delivering a Groundbreaking, First-in-Class Therapy to Patients in Need
Veristat Appoints Industry Veteran Kim McLean Boericke as its Chief Operating Officer
Accelerating Operational Excellence and Client Success
SOUTHBOROUGH, MA – October 30, 2024—Veristat, a scientific-minded global clinical...
Veristat Appoints Gabriela Rosu, M.D., to Lead Growing Medical Affairs Team
To support sponsors around the globe bringing novel treatments to patients
SOUTHBOROUGH, MA – May 29, 2024 – Veristat, the Science-First...
Veristat Joins the Alliance for Regenerative Medicine (ARM) to Help Address Critical Issues...
Committed to a Science-First Approach to Support Patient Access to Life-Changing Therapies
Veristat Acquires Biometrics-focused Instat Clinical Research
Acquisition Will Power Data insights, Trial Optimization, and Value Across Clinical Development
Veristat Acquires European Medical Writing Consultancy Scinopsis
Expands Medical Writing Team, Helping Sponsors Communicate the Value of Their Data Globally
Veristat Congratulates HIPRA for EMA Approval of Its BIMERVAX® COVID-19 Vaccine
Veristat Delivered a Full Range of Clinical Trial Services Culminating in Marketing Authorization of HIPRA’s SARS-CoV-2 Vaccine and...
Veristat Supported Eight Regulatory Approvals in 2022, the Majority for Therapies Designed...
Supporting Its Continued Commitment During Rare Disease Month to Making a Difference in the Lives of Patients Faced with Limited Treatment...
Veristat Presents Integrated, Customized DCT Solutions at the DTRA Annual Meeting
Highlights the unique advantages its DCT solutions hold for small to mid-size biotechs conducting trials for complex diseases